Author:
Calvagna Giuseppe Mario,Patanè Salvatore
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference26 articles.
1. Madan S, Shah S, Partovi S, Parikh SA. Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther. 2014;4(4):314–23. doi: 10.3978/j.issn. 2223-3652.2014.08.01 .
2. Kaski JC. New challenges ahead for the newer oral thrombin inhibitors that aim at replacing warfarin in clinical practice-any role for scientific societies in the debate? Cardiovasc Drugs Ther. 2012;26(4):359–60. doi: 10.1007/s10557-012-6393-1 .
3. Jalota A, Scarabelli TM, Saravolatz L, Bakhsh MU, Agrawal P, Jalota R, et al. Novel anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28(3):247–62. doi: 10.1007/s10557-014-6524-y .
4. Kwong JS, Lam YY, Yan BP, Yu CM. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther. 2013;27(1):23–35. doi: 10.1007/s10557-012-6426-9 .
5. Strobeck JE. Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants. Cardiovasc Drugs Ther. 2012;26(4):331–8. doi: 10.1007/s10557-012-6396-y .
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献